ReviewPrecision radiation oncology2024
Revolutionizing cancer treatment: The role of radiopharmaceuticals in modern cancer therapy.
Review in Precision radiation oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Targeted tumor starvation strategy augments radiosensitivity and enhances radioactive iodine-mediated tumor immunotherapy.Acta pharmacologica Sinica · 2026Article
- Activation of tumor-specific CD8+ T cells prior to radiopharmaceutical therapy improves antitumor response.Journal for immunotherapy of cancer · 2026Article
- Emerging role of radiopharmaceutical therapy in oncology: advances, challenges, and future directions.JNCI cancer spectrum · 2026Review
- The use of mass cytometry (CyTOF) to evaluate the cellular uptake of stable radiopharmaceutical surrogates in single cells: a proof-of-concept study.EJNMMI radiopharmacy and chemistry · 2026Article
- Chromatin Nano-Organization in Peripheral Blood Mononuclear Cells After In-Solution Irradiation with the Beta-Emitter Lu-177.Biomolecules · 2026Article
- Radiopharmaceutical: An Update and Comparison of Preclinical Investigation Result of Alpha and Beta Emitter Radioisotope.Drug design, development and therapy · 2026Review
- Integrative Multiomics and Single-Cell Analyses Identify FKBP10 as a Predictor of Radiotherapy Outcome in Colorectal Cancer.Human mutation · 2026Article
- Upregulation of spondin-2 indicates poorer clinical outcomes and induces radioresistance in gastric cancer.Translational cancer research · 2025Article
- The Ballet of Natural-Product: Carrier-Free "Triadic" Drug Delivery Platforms for Enhanced Tumor Treatment.Journal of functional biomaterials · 2025Review
- A nomogram for predicting overall survival in advanced hepatocellular carcinoma patients receiving radiotherapy combined with targeted therapy: a multicenter retrospective study.Translational cancer research · 2025Article
- Article
- Single-cell transcriptome sequencing reveals tumor stem cells and their molecular characteristics in intrahepatic cholangiocarcinoma.Scientific reports · 2025Article
- Optimizing Cancer Treatment: Exploring the Role of AI in Radioimmunotherapy.Diagnostics (Basel, Switzerland) · 2025Review
- The use of radiopharmaceuticals in targeted cancer therapy: a narrative review.International journal of physiology, pathophysiology and pharmacology · 2025Review
- Revolutionizing cancer treatment: The role of radiopharmaceuticals in modern cancer therapy.Precision radiation oncology · 2024Review
- β-Elemene promotes ferroptosis and reverses radioresistance in gastric cancer by inhibiting the OTUB1-GPX4 interaction.Frontiers in pharmacology · 2024Article
- Synthesis and Preclinical Evaluation of 188Re-MAX-HEDP: A Promising Theranostics Strategy for Bone Metastases.Iranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiopharmaceutical therapy (RPT) is a precision medicine approach that involves the targeted delivery of radioactive atoms to tumor cells, representing a breakthrough strategy for cancer treatment. Radiopharmaceuticals typically consist of a small amount of radioactive material, a radionuclide, paired with a chemical that specifically targets the cell. Some radionuclides naturally target specific cells or biological processes without the need for modification. RPT is a novel cancer treatment method that offers various advantages over current traditional treatment approaches. One of the primary advantages of RPT is its ability to target cancer cells, including those in metastatic areas. Another key advantage of RPT is that radiation can be delivered systemically, locally, or physiologically to specific cells internally rather than being applied externally. Moreover, radiotracer imaging can be utilized to determine radiopharmaceutical absorption in target tissues before providing a therapeutic dose. Compared to all other cancer treatment approaches, RPT has demonstrated high efficacy with minimal toxicity. The recent approval of multiple RPT medicines by the US Food and Drug Administration highlights the tremendous potential of this treatment. This article provides a detailed review of RPT, including insights into manufacturing procedures, safety measures, and its applications in cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.